EUVIMEDEUVIMED entdecken
Crossref

Construction and Validation of a Prediction Model for TACE Resistance in Hepatocellular Carcinoma Based on Contrast-Enhanced Ultrasound Radiomics

Zhibin Wu, Lutan Yan, Lin Zhou, Xiaoli Shi, Xiaohui Wang

British Journal of Radiology · 14.11.2026

DOI: 10.1093/bjr/tqag281 ↗

Kurz gefasst

Fachartikel in der Zeitschrift British Journal of Radiology, online erschienen am 14.11.2026. Verfasst von Zhibin Wu und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Ultrasound Medicine, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan 450052, China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

To construct and validate a contrast-enhanced ultrasound (CEUS) radiomics-clinical model for predicting transarterial chemoembolization (TACE) resistance in hepatocellular carcinoma (HCC).

Methods

A total of 168 HCC patients who underwent CEUS on two vendor platforms (Philips E9 and GE Logiq E95) were split into a training set (n = 118) and an internal validation set (n = 50), with an additional 80 patients forming an external validation cohort. For each patient, 2D regions of interest were manually delineated on the largest cross-sectional slice of each CEUS phase. Radiomic features were extracted and screened by LASSO regression; the twelve retained features were linearly combined into a single Rad-score. The Rad-score and three prespecified clinical risk factors (tumor size, Child-Pugh class, AFP) confirmed by multivariate analysis were combined into a parsimonious logistic regression (LR) model with four predictors in total. Performance was assessed by ROC curve, calibration curve, decision curve analysis (DCA), subgroup analysis, and prospective validation.

Results

The combined model had AUCs of 0.895, 0.891 and 0.846 in three sets, with subgroup AUCs >0.86. Prospective validation showed TACE plus sorafenib improved 6-month response rate from 26.7% to 53.3% for high-risk patients.

Conclusion

The CEUS radiomics-clinical model accurately predicts TACE resistance, guiding individualized HCC treatment. Advances in Knowledge This model integrates CEUS multi-phase radiomics and clinical factors, outperforming single clinical/radiomic models. Strict multi-step screening and comprehensive validation avoid data leakage, ensuring robust prediction and clinical translatability.

Schlagwörter

Stichwörter der Autor:innen

CarcinomaChemoembolizationContrast-enhanced ultrasonography (CEUS)Drug ResistanceHepatocellularModelsNeoplasmRadiomicsTheoreticalTherapeutic (TACE)

Autor:innen und Institutionen

  • Department of Ultrasound Medicine, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan 450052, China.
  • Department of Pharmacy, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan 450052, China.

Zitieren

APA

Wu, Z., Yan, L., Zhou, L., Shi, X., & Wang, X. (2026). Construction and Validation of a Prediction Model for TACE Resistance in Hepatocellular Carcinoma Based on Contrast-Enhanced Ultrasound Radiomics. British Journal of Radiology. https://doi.org/10.1093/bjr/tqag281

Vancouver

Wu Z, Yan L, Zhou L, Shi X, Wang X. Construction and Validation of a Prediction Model for TACE Resistance in Hepatocellular Carcinoma Based on Contrast-Enhanced Ultrasound Radiomics. British Journal of Radiology. 2026. doi:10.1093/bjr/tqag281

BibTeX
@article{Wu2026,
  author = {Wu, Zhibin and Yan, Lutan and Zhou, Lin and Shi, Xiaoli and Wang, Xiaohui},
  title = {Construction and Validation of a Prediction Model for TACE Resistance in Hepatocellular Carcinoma Based on Contrast-Enhanced Ultrasound Radiomics},
  journal = {British Journal of Radiology},
  year = {2026},
  doi = {10.1093/bjr/tqag281}
}
Kostenlos starten →